Pharmacokinetic comparison of the vasorelaxant compound ferulic acid following the administration of Guanxin II to healthy volunteers and patients with angina pectoris

Li,Yun-Hui; Huang,Xi; Wang,Yang; Fan,Rong; Zhang,Hong-Min; Ren,Ping; Chen,Yao; Zhou,Hong-Hao; Liu,Zhao-Qian; Liang,Yi-Zeng; Lu,Hong-Mei

doi:10.3892/etm.2013.1302

Pharmacokinetic comparison of the vasorelaxant compound ferulic acid following the administration of Guanxin II to healthy volunteers and patients with angina pectoris

Authors:
- Yun-Hui Li
- Xi Huang
- Yang Wang
- Rong Fan
- Hong-Min Zhang
- Ping Ren
- Yao Chen
- Hong-Hao Zhou
- Zhao-Qian Liu
- Yi-Zeng Liang
- Hong-Mei Lu
View Affiliations

Affiliations: Laboratory of Ethnopharmacology, Department of Integrated Chinese and Western Medicine, The National Key Clinical Specialist Vocational School, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Laboratory of Ethnopharmacology, Department of Integrated Chinese and Western Medicine, The National Key Clinical Specialist Vocational School, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Henan Eye Institute and Department of Ophthalmology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China, TCM Pharmacogenetics Laboratory, Central South University, Changsha, Hunan 410008, P.R. China, College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan 410083, P.R. China
Published online on: September 17, 2013 https://doi.org/10.3892/etm.2013.1302
Pages: 1283-1289

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Coronary heart disease (CHD) is the leading cause of mortality worldwide. The Chinese medicinal formula Guanxin II has been shown to have a favorable effect in the attenuation of angina. The aim of this study was to compare the pharmacokinetics of ferulic acid (FA), which is a vasorelaxant compound present in Guanxin II, in healthy volunteers and patients with angina pectoris following the administration of Guanxin II. Ex vivo experiments were performed in order to investigate the vasorelaxant effect of FA on the human internal mammary artery (IMA) to provide evidence that it is a bioactive component of Guanxin II. Following the oral administration of Guanxin II, the FA levels in the serum were quantified by a simple and rapid high-performance liquid chromatography (HPLC) method. Treatment with FA (10-8-10-3 M) caused a concentration‑dependent relaxation of endothelial IMA rings following precontraction with KCl. Statistically significant differences were identified between the pharmacokinetic parameters Cmax, t1/2α, t1/2β and t1/2Ka of the healthy volunteers and the patients with angina pectoris following the oral administration of Guanxin II. FA is a bioactive compound absorbed from Guanxin II that attenuates angina pectoris, a condition that may modify the pharmacokinetics of FA. Not only do the pharmacokinetic parameters direct the clinical use of Guanxin II, but they may also be useful for exploring the pathology of angina pectoris.

View Figures

View References

1.	Thom T, Haase N, Rosamond W, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 113:e85–e151. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Murphy SL, Xu JQ and Kochanek MA; Division of Vital Statistics: Deaths: Preliminary data for 2010. National Vital Statistics Reports. 60:1–68. 2012.
3.	He L, Tang X, Song Y, et al: Prevalence of cardiovascular disease and risk factors in a rural district of Beijing, China: a population-based survey of 58,308 residents. BMC Public Health. 12:342012. View Article : Google Scholar : PubMed/NCBI
4.	Nabel EG and Braunwald E: A tale of coronary artery disease and myocardial infarction. N Eng J Med. 366:54–63. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Lenfant C: Chest pain of cardiac and noncardiac origin. Metabolism. 59(Suppl 1): S41–S46. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Abrams J: Clinical practice. Chronic stable angina. N Engl J Med. 352:2524–2533. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Barre J, Houin G, Brunner F, et al: Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res. 3:215–226. 1983.PubMed/NCBI
8.	Ventresca GP and Mariani L: Disease states and changes in drug pharmacokinetics. Clin Ter. 47:131–144. 1996.(In Italian).
9.	Qin F, Huang X, Zhang HM and Ren P: Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San in healthy volunteers and patients with functional dyspepsia: influence of disease state. J Pharm Pharmacol. 61:125–129. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Cho EJ, Yokozawa T and Okamoto T: Protective effect of Chinese prescription Kangen-karyu and its crude drug Tanjin against age-related lipidosis in rats. J Pharm Pharmacol. 59:687–694. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Huang X, Qin F, Zhang HM, et al: Cardioprotection by Guanxin II in rats with acute myocardial infarction is related to its three compounds. J Ethnopharmacol. 121:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Qin F, Liu YX, Zhao HW, et al: Chinese medicinal formula Guan-Xin-Er-Hao protects the heart against oxidative stress induced by acute ischemic myocardial injury in rats. Phytomedicine. 61:215–221. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Xu R, Huang X, Li Y, et al: Clinical observation of treating coronary heart disease with Guan-xin-er-hao. Journal of Chengdu University of Traditional Chinese Medicine. 24(4): 17–19. 2001.(In Chinese).
14.	Zhao HW, Qin F, Liu YX, et al: Antiapoptotic mechanisms of Chinese medicine formula Guan-Xin-Er-Hao in the rat ischemic heart. Tohoku J Exp Med. 216:309–316. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Zhao J, Huang X, Tang W, et al: Effect of oriental herbal prescription Guan-Xin-Er-Hao on coronary flow in healthy volunteers and antiapoptosis on myocardial ischemia-reperfusion in rat models. Phytother Res. 21:926–931. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Qiao X, Han J, Xu M, et al: Characterization of chemical constituents in Guan Xin II decoction by liquid chromatography coupled with electrospray ionization-mass spectrometry. Planta Med. 74:1720–1729. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Wang Y, Huang X, Qin F, et al: A strategy for detecting optimal ratio of cardioprotection-dependent three compounds as quality control of guan-xin-er-hao formula. J Ethnopharmacol. 133:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Guo GP, Ye Y, Li L, et al: Endothelium-independent vasorelaxant effect of sodium ferulate on rat thoracic aorta. Life Sci. 84:81–88. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Wang L, Wang Z, Wo S, et al: A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to Si Wu Tang. Int J Pharm. 406:99–105. 2011. View Article : Google Scholar
20.	Qiu XJ, Huang X, Chen ZQ, et al: Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. J Ethnopharmacol. 137:205–213. 2011. View Article : Google Scholar
21.	Li Y, Liu C, Zhang Y, et al: Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. J Ethnopharmacol. 137:562–567. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Li FQ, Xu S, Su H, et al: Development of a gradient reversed-phase HPLC method for the determination of sodium ferulate in beagle dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 846:319–322. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Li Y and Bi K: HPLC determination of ferulic acid in rat plasma after oral administration of Rhizoma Chuanxiong and its compound preparation. Biomed Chromatogr. 17:543–546. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Qi J, Jin X, Huang L and Ping Q: Simultaneous determination of hydroxysafflor yellow A and ferulic acid in rat plasma after oral administration of the co-extractum of Rhizoma chuanxiong and Flos Carthami by HPLC-diode array detector. Biomed Chromatogr. 21:816–822. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Yang C, Tian Y, Zhang Z, et al: High-performance liquid chromatography-electrospray ionization mass spectrometry determination of sodium ferulate in human plasma. J Pharm Biomed Anal. 43:945–950. 2007. View Article : Google Scholar
26.	Kern P: Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP/ICH). Parasitol Int. 55:S273–S282. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Suzuki A, Yamamoto M, Jokura H, et al: Ferulic acid restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats. Am J Hypertens. 20:508–513. 2007. View Article : Google Scholar
28.	Sullivan JM and Lobo RA: Considerations for contraception in women with cardiovascular disorders. Am J Obstet Gynecol. 168:2006–2011. 1993. View Article : Google Scholar : PubMed/NCBI